Lilly Cheng Immergluck1, Trisha Chan Parker2, Shabnam Jain3, Elham Laghaie2, Philip Spandorfer4, Robert C Jerris5, Michael D Bowen6, Umesh D Parashar6, Margaret M Cortese6. 1. Departments of Microbiology, Biochemistry, Immunology, and Pediatrics, Morehouse School of Medicine, Atlanta, GA; Clinical Research Center, Morehouse School of Medicine, Atlanta, GA; Children's Healthcare of Atlanta, Atlanta, GA. Electronic address: limmergluck@msm.edu. 2. Departments of Microbiology, Biochemistry, Immunology, and Pediatrics, Morehouse School of Medicine, Atlanta, GA; Clinical Research Center, Morehouse School of Medicine, Atlanta, GA. 3. Children's Healthcare of Atlanta, Atlanta, GA; Department of Pediatrics, Emory University, Atlanta, GA. 4. Pediatric Emergency Medicine Associates, Atlanta, GA. 5. Children's Healthcare of Atlanta, Atlanta, GA; Department of Pathology, Emory University, Atlanta, GA. 6. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA.
Abstract
OBJECTIVE: Using case-control methodology, we measured the vaccine effectiveness (VE) of the 2-dose monovalent rotavirus vaccine (RV1) and 3-dose pentavalent rotavirus vaccine (RV5) series given in infancy against rotavirus disease resulting in hospital emergency department or inpatient care. STUDY DESIGN: Children were eligible for enrollment if they presented to any 1 of 3 hospitals in Atlanta, Georgia with diarrhea ≤10 days duration during January-June 2013 and were born after RV1 introduction. Stool samples were tested for rotavirus by enzyme immunoassay and immunization records were obtained from providers and the state electronic immunization information system. Case-subjects (children testing rotavirus antigen-positive) were compared with children testing rotavirus antigen-negative. RESULTS: Overall, 98 rotavirus-case subjects and 175 rotavirus-negative controls were enrolled. Genotype G12P[8] predominated (n = 87, 89%). The VE of 2 RV1 doses was 84% (95% CI 38, 96) among children aged 8-23 months and 82% (95% CI 41, 95) among children aged ≥24 months. For the same age groups, the VE of 3 RV5 doses was 80% (95% CI 27, 95) and 87% (95% CI 22, 98), respectively. CONCLUSIONS: Under routine use, the RV1 and RV5 series were both effective against moderate-to-severe rotavirus disease during a G12P[8] season, and both vaccines demonstrated sustained protection beyond the first 2 years of life.
OBJECTIVE: Using case-control methodology, we measured the vaccine effectiveness (VE) of the 2-dose monovalent rotavirus vaccine (RV1) and 3-dose pentavalent rotavirus vaccine (RV5) series given in infancy against rotavirus disease resulting in hospital emergency department or inpatient care. STUDY DESIGN:Children were eligible for enrollment if they presented to any 1 of 3 hospitals in Atlanta, Georgia with diarrhea ≤10 days duration during January-June 2013 and were born after RV1 introduction. Stool samples were tested for rotavirus by enzyme immunoassay and immunization records were obtained from providers and the state electronic immunization information system. Case-subjects (children testing rotavirus antigen-positive) were compared with children testing rotavirus antigen-negative. RESULTS: Overall, 98 rotavirus-case subjects and 175 rotavirus-negative controls were enrolled. Genotype G12P[8] predominated (n = 87, 89%). The VE of 2 RV1 doses was 84% (95% CI 38, 96) among children aged 8-23 months and 82% (95% CI 41, 95) among children aged ≥24 months. For the same age groups, the VE of 3 RV5 doses was 80% (95% CI 27, 95) and 87% (95% CI 22, 98), respectively. CONCLUSIONS: Under routine use, the RV1 and RV5 series were both effective against moderate-to-severe rotavirus disease during a G12P[8] season, and both vaccines demonstrated sustained protection beyond the first 2 years of life.
Authors: Jennifer J Hull; Elizabeth N Teel; Tara K Kerin; Molly M Freeman; Mathew D Esona; Jon R Gentsch; Margaret M Cortese; Umesh D Parashar; Roger I Glass; Michael D Bowen Journal: Pediatr Infect Dis J Date: 2011-01 Impact factor: 2.129
Authors: K B Phua; F S Lim; Y L Lau; E A S Nelson; L M Huang; S H Quak; B W Lee; Y L Teoh; H Tang; I Boudville; L C Oostvogels; P V Suryakiran; I V Smolenov; H H Han; H L Bock Journal: Vaccine Date: 2009-08-11 Impact factor: 3.641
Authors: Penelope H Dennehy; Margaret M Cortese; Rodolfo E Bégué; Jenifer L Jaeger; Nancy E Roberts; Rongping Zhang; Philip Rhodes; John Gentsch; Richard Ward; David I Bernstein; Charles Vitek; Joseph S Bresee; Mary Allen Staat Journal: Pediatr Infect Dis J Date: 2006-12 Impact factor: 2.129
Authors: Jennifer E Cortes; Aaron T Curns; Jacqueline E Tate; Margaret M Cortese; Manish M Patel; Fangjun Zhou; Umesh D Parashar Journal: N Engl J Med Date: 2011-09-22 Impact factor: 91.245
Authors: Daniel C Payne; Julie A Boom; Mary Allen Staat; Kathryn M Edwards; Peter G Szilagyi; Eileen J Klein; Rangaraj Selvarangan; Parvin H Azimi; Christopher Harrison; Mary Moffatt; Samantha H Johnston; Leila C Sahni; Carol J Baker; Marcia A Rench; Stephanie Donauer; Monica McNeal; James Chappell; Geoffrey A Weinberg; Azadeh Tasslimi; Jacqueline E Tate; Mary Wikswo; Aaron T Curns; Iddrisu Sulemana; Slavica Mijatovic-Rustempasic; Mathew D Esona; Michael D Bowen; Jon R Gentsch; Umesh D Parashar Journal: Clin Infect Dis Date: 2013-03-13 Impact factor: 9.079
Authors: Eyal Leshem; Rebecca E Moritz; Aaron T Curns; Fangjun Zhou; Jacqueline E Tate; Benjamin A Lopman; Umesh D Parashar Journal: Pediatrics Date: 2014-06-09 Impact factor: 7.124
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Jordan E Cates; Avnika B Amin; Jacqueline E Tate; Ben Lopman; Umesh Parashar Journal: Pediatr Infect Dis J Date: 2021-12-01 Impact factor: 2.129
Authors: Corinne Willame; Marije Vonk Noordegraaf-Schouten; Emilia Gvozdenović; Katrin Kochems; Anouk Oordt-Speets; Nicolas Praet; Rosa van Hoorn; Dominique Rosillon Journal: Open Forum Infect Dis Date: 2018-11-12 Impact factor: 3.835
Authors: Andrew Clark; Jacqueline Tate; Umesh Parashar; Mark Jit; Mateusz Hasso-Agopsowicz; Nicholas Henschke; Benjamin Lopman; Kevin Van Zandvoort; Clint Pecenka; Paul Fine; Colin Sanderson Journal: Lancet Glob Health Date: 2019-11 Impact factor: 26.763